Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more
Enanta Pharmaceuticals Inc (ENTA) - Total Assets
Latest total assets as of December 2025: $329.50 Million USD
Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) holds total assets worth $329.50 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Enanta Pharmaceuticals Inc - Total Assets Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Enanta Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (September 2025)
Enanta Pharmaceuticals Inc's total assets of $329.50 Million consist of 72.8% current assets and 27.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.5% |
| Accounts Receivable | $6.88 Million | 2.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enanta Pharmaceuticals Inc's current assets represent 72.8% of total assets in 2025, a decrease from 96.2% in 2011.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2025, down from 26.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 2.5% of total assets.
Enanta Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Enanta Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Enanta Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Enanta Pharmaceuticals Inc generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Enanta Pharmaceuticals Inc is currently not profitable relative to its asset base.
Enanta Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.44 | 5.47 | 16.09 |
| Quick Ratio | 4.44 | 5.47 | 16.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $153.96 Million | $ 219.09 Million | $ 401.60 Million |
Enanta Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Enanta Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.18 |
| Latest Market Cap to Assets Ratio | 0.95 |
| Asset Growth Rate (YoY) | -25.5% |
| Total Assets | $280.73 Million |
| Market Capitalization | $268.04 Million USD |
Valuation Analysis
Near Book Valuation: The market values Enanta Pharmaceuticals Inc's assets close to their book value ( 0.95x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Enanta Pharmaceuticals Inc's assets decreased by 25.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual total assets of Enanta Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $280.73 Million | -25.47% |
| 2024-09-30 | $376.65 Million | -18.52% |
| 2023-09-30 | $462.27 Million | +21.46% |
| 2022-09-30 | $380.59 Million | -13.67% |
| 2021-09-30 | $440.86 Million | -10.17% |
| 2020-09-30 | $490.79 Million | +0.20% |
| 2019-09-30 | $489.83 Million | +18.25% |
| 2018-09-30 | $414.23 Million | +26.82% |
| 2017-09-30 | $326.64 Million | +16.13% |
| 2016-09-30 | $281.28 Million | +14.33% |
| 2015-09-30 | $246.01 Million | +58.29% |
| 2014-09-30 | $155.41 Million | +32.86% |
| 2013-09-30 | $116.97 Million | +124.25% |
| 2012-09-30 | $52.16 Million | +99.89% |
| 2011-09-30 | $26.10 Million | -- |